<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972907</url>
  </required_header>
  <id_info>
    <org_study_id>RDD 104</org_study_id>
    <nct_id>NCT00972907</nct_id>
  </id_info>
  <brief_title>An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects</brief_title>
  <official_title>An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RDD Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RDD Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study. The study will consist of 1 treatment group: coated Nifedipine&#xD;
      suppository containing 12 mg of Nifedipine, administered BID to subjects with chronic anal&#xD;
      fissure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label study. The study will consist of 1 treatment group: coated Nifedipine&#xD;
      suppository containing 12 mg of Nifedipine. Approximately 20 subjects will participate into&#xD;
      this 8-week study. A screening visit will be used to determine subject suitability for&#xD;
      inclusion in the trial. Within one week of the screening visit, subjects who meet all&#xD;
      inclusion criteria and none of the exclusion criteria will receive Coated Nifedipine 12 mg&#xD;
      Suppository X2 a day (BID) (24 mg/day total) for a period of 8 weeks. During this period, 4&#xD;
      study visits (at 0, 2, 5, and 8 weeks) will take place. Study medication will be administered&#xD;
      BID (in the morning and in the evening). In addition to receiving study medication, subjects&#xD;
      will be maintained on a standard treatment for Anal Fissure: sitz baths, high fiber diet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To examine the effect of coated Nifedipine suppository on Anal fissure pain.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To examine the effect of coated Nifedipine suppository on Anal fissure healing.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the Safety and tolerability of coated Nifedipine suppositories in Anal Fissure patients.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Anal Fissure</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nifedipine coated suppositories BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine coated suppositories</intervention_name>
    <description>12 mg Nifedipine coated suppositories BID</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Single anal fissure&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Male or female subjects 18 to 65 years of age&#xD;
&#xD;
          -  Has chronic anal fissure defined as history of anal pain at least three days a week&#xD;
             for 30 days duration or more&#xD;
&#xD;
          -  Visible fibers of the internal sphincter were seen at the base of the fissure or if a&#xD;
             sentinel pile was present&#xD;
&#xD;
          -  VAS of &gt; 35 mm in screening visit&#xD;
&#xD;
          -  If female, is nonlactating, has a negative urine pregnancy test result, and does not&#xD;
             plan on becoming pregnant during the study, or not of childbearing potential&#xD;
             (hysterectomy or tubal ligation at least 6 months prior to entry to the study or&#xD;
             post-menopausal for 1 year); if of childbearing potential (including peri-menopausal&#xD;
             women who have had a menstrual period within one year) must practice or be willing to&#xD;
             continue to practice appropriate birth control (such as implants, injectables, oral&#xD;
             contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal&#xD;
             ligation, or a vasectomized partner) during the entire study duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to Nifedipine, polyethylene-glycol, propylene Glycol or silicone&#xD;
&#xD;
          -  Fissure resulting from inflammatory bowel disease, venereal disease, perianal&#xD;
             psoriasis, immunodeficiency syndrome&#xD;
&#xD;
          -  Anal abscess&#xD;
&#xD;
          -  Fixed anal stenosis&#xD;
&#xD;
          -  Active or past history of cardiovascular or cerebrovascular disease including unstable&#xD;
             angina, myocardial infarction, transient ischemic attacks/stroke, clinically&#xD;
             significant arrhythmia, moderate to severe congestive heart failure, or cardiac valve&#xD;
             abnormalities&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Insulin treated type 2 diabetes mellitus&#xD;
&#xD;
          -  History of Renal insufficiency&#xD;
&#xD;
          -  History of Liver insufficiency&#xD;
&#xD;
          -  Malignant disease within 5 years of screening&#xD;
&#xD;
          -  Has uncontrolled hypertension (sitting blood pressure &lt;160/95 mmHg at screening)&#xD;
&#xD;
          -  History of chronic gastrointestinal disease&#xD;
&#xD;
          -  History of rectal surgery&#xD;
&#xD;
          -  History of gastrointestinal surgery&#xD;
&#xD;
          -  History of HIV, hepatitis B, hepatitis C&#xD;
&#xD;
          -  In need of chronic use of medication, with the exception of birth control medications&#xD;
&#xD;
          -  Currently uses medication for acute illness (other than medications for use of&#xD;
             treatment/pain relief of anal fissure)&#xD;
&#xD;
          -  Has used, in the last four weeks, drugs that may affect blood coagulation, such as&#xD;
             Aspirin at a dose higher than 500 mg/day , Warfarin, Sintrom, Enoxaparin, Nadroparin,&#xD;
             Heparin, Clopidogrel, Ticlopidine&#xD;
&#xD;
          -  Is using drug that may affect rectal tone&#xD;
&#xD;
          -  Calcium Channel Blocker such as:&#xD;
&#xD;
               -  Nifedipine (Osmo-Adlat, Pressolat, Nifedipine -Teva, Nifedilong)&#xD;
&#xD;
               -  Amlodipine (Amlow, Norvasc, Amlodipine-Teva)&#xD;
&#xD;
               -  Lercadipine (Vasodip)&#xD;
&#xD;
               -  Verapamil (Ikacor, Ikapress, Verapress)&#xD;
&#xD;
               -  Felodipine (Penedil)&#xD;
&#xD;
               -  Diltiazem (Adizem, Dilatam)&#xD;
&#xD;
          -  Nitrate donors such as:&#xD;
&#xD;
               -  Glyceryl Trinitrate (Deponit)&#xD;
&#xD;
               -  Isosorbid dinitrate (Isoket, Isolong)&#xD;
&#xD;
               -  Isosrbid mononitrate (Monocord, Monolong, Mononit)&#xD;
&#xD;
               -  Nitroglycerine (Nitrocine, Nitroderm, Nitrolingual)&#xD;
&#xD;
          -  Has upon physical examination a rectal deformation or signs of rectal disease such as&#xD;
             bleeding hemorrhoids, fistula., infection or space occupying lesion&#xD;
&#xD;
          -  Is an immediate family member of personnel directly affiliated with the study at the&#xD;
             investigative site, or is personally directly affiliated with the study at the&#xD;
             investigative site; or is employed by RDD Pharma Ltd&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sapir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macabi HMO</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>February 15, 2011</last_update_submitted>
  <last_update_submitted_qc>February 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Nir Barak MD</name_title>
    <organization>RDD Pharma LTD</organization>
  </responsible_party>
  <keyword>anal fissure</keyword>
  <keyword>pain</keyword>
  <keyword>nifedipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fissure in Ano</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

